New York, New York (NetworkNewsWire) – The hazards of
pharmacology have hardly changed since Paracelsus, a famous
Renaissance physician, astoundingly declared that it was only the
dosage that separated a medicine from a poison, bundled with
adverse side effects. Despite considerable advances in medicine,
many medications are still as injurious as their Renaissance
precursors. Nevertheless, recent developments in drug delivery
technologies increasingly suggest that safer, more efficient
treatment options are on the horizon. At the core of this potential
are cannabinoids. Developments in this rapidly growing segment of
the medical marijuana market are pioneered by a vast number of
innovators, including Lexaria Bioscience Corp. (CSE: LXX)
(OTCQB: LXRP) (LXRP
Profile), GW Pharmaceuticals
(NASDAQ: GWPH), Zynerba Pharmaceuticals (NASDAQ: ZYNE),
Cara Therapeutics (NASDAQ: CARA) and
Philip Morris (NYSE: PM), all of which are
invested in the cannabis space.
Research findings in the cannabinoid field continue to astonish
and elate. In August 2017, Lexaria Bioscience announced (http://nnw.fm/h7aG8) the world's first clinical study
on human volunteers of cannabidiol (CBD) within Lexaria's high
absorption TurboCBD™ product. The study will evaluate the effects
of CBD on cardiovascular health and cognitive function. Lexaria’s
TurboCBD, a brand of technologically enhanced, high absorption hemp
oil capsules, came to market in March 2017. Its CBD content is
fortified with high-quality American ginseng and ginkgo biloba for
support of enhanced focus and memory, and reduced stress and
fatigue.
TurboCBD capsules contain a combination of CBD and minute
quantities of long chain fatty acids like sunflower oil, utilizing
a proprietary technology to create an amalgam that increases the
ability of the human gastrointestinal system to absorb CBD. In
vitro and human focus study testing has shown increases in CBD
absorption using Lexaria’s technology by as much as 5-10 times more
than conventional preparations. Those studies also demonstrated
rapid onset of action in as little as 15 minutes.
The TurboCBD study is designed to test a number of hypotheses
expected to follow after its supplementation: (i) that circulating
CBD and nitric oxide will increase in both young and old
participants; (ii) that glucose and blood pressure will remain
stable; and (iii) that vascular function, and cognitive and
physical exercise performance will improve to a greater extent in
older participants. The study will be conducted by researchers at
the University of British Columbia, which has consistently been
ranked as one of the top three universities in Canada. The
institution is also considered one of the top research universities
in the world and has conducted several earlier studies in the
cannabis sector, available for review at http://nnw.fm/o8O9a.
Lexaria has also developed and commercialized a patented and
cost-effective delivery technology, DehydraTECH™, which has been
both laboratory and market proven to enhance the performance of
beneficial compounds in ingestible products across four categories:
taste, smell, speed of action, and bio-absorption and
bio-availability.
At present, Lexaria is the only company in the world that has
been awarded a patent for the improved (oral or ingestible,
including pills) delivery of all non-psychoactive cannabinoids.
Patents have been awarded in the U.S. and Australia and are pending
in 40 more countries. This puts the company in the unusually
advantageous position of owning proprietary technology that can
deliver a vast range of non-psychoactive cannabinoid-based
drugs.
Notably, because Lexaria’s technology is complimentary to all
ingested forms of cannabinoids, the company is positioned to
license its intellectual property to clinical-stage biotechnology
companies, becoming an enabler – rather than a competitor - that
works with other research and development pertaining to
cannabinoids.
Collaboration with a company like GW
Pharmaceuticals (GWPH), for example,
would could yield considerable outcomes. The British company, best
known for its multiple sclerosis (MS) cannabinoid product, Sativex,
is working feverishly to bring another to market. Currently, its
lead cannabinoid product candidate Epidiolex is in phase III
clinical trials. This drug is a proprietary oral solution of pure
plant-derived cannabidiol (CBD) for the treatment of severe,
orphan, early-onset, treatment-resistant epilepsy syndromes
including Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous
Sclerosis Complex (TSC) and Infantile Spasms (IS).
Also developing treatments for epileptic conditions, with rather
less encouraging outcomes than GW Pharmaceuticals, is
Zynerba Pharmaceuticals (ZYNE).
In August 2017, the company published disappointing results of
phase II studies of its cannabidiol (CBD) product, ZYN002, aimed at
treating adult epilepsy patients with focal seizures. Since CBD has
shown some promise in reducing epileptic seizures, as in the GW
Pharmaceutical studies, this raises the possibility that Zynerba’s
setback may be due, not to the payload, but the delivery system.
ZYN002 employs a transdermal gel that is applied topically on the
surface of the skin. However, an oral delivery system, like the one
developed by Lexaria, may prove more effective.
Cara Therapeutics (CARA) is another biotech now
coming to terms with disappointing clinical trial results. Trials
for an oral formulation of its drug candidate CR845, an opioid
derivative, studied in osteoarthritis patients, did not turn out so
well. However, the study tested patients on low dosages (1.0 mg and
2.5 mg) of CR845 taken orally. Higher oral dosages and CR845 taken
intravenously have shown more promising outcomes. The company’s
research into opioids has spilled over into cannabinoids. Current
preclinical research involves CR701, a cannabinoid receptor
agonist, designed to treat chronic pain. The incentive to develop
cannabinoid products to treat chronic pain is driven, in part, by
the opioid epidemic. While opioid overdose deaths are in the tens
of thousands, there appears to be no clearly documented account of
anyone dying from an overdose of marijuana.
Smoking marijuana is, of course, one method proven to deliver
cannabinoids effectively. Alas, the now well-known deleterious
effects on the respiratory system are spurring efforts to develop
other delivery mechanisms, such as non-smoke cigarettes, which
perhaps is why Philip Morris International (PM)
invested $20 million in Israeli startup Syqe Medical. The company
manufactures delivery devices for cannabis, like its inhaler.
Syqe’s pocket-sized Inhaler delivers precision dosages of its
payload: 100 micrograms, every time the device is activated. This
overcomes a major barrier to adoption of medical cannabis by
doctors: the lack of standardization in dosage regimens. Syqe has
tested a similar device in hospitals in a clinical trial that
demonstrated its dosing precision superiority to other modes of THC
administration. With Philip Morris’ involvement, nicotine may just
be next.
As the research into cannabinoids continues to unearth
excitingly novel ways to treat a variety of medical conditions,
delivery systems are proving to be just an important as payloads.
As a result, companies with advanced delivery systems, like
Lexaria, are likely to find cannabinoid biotechs beating that
proverbial path to their door.
For more information on Lexaria Bioscience please visit:
Lexaria
Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
NetworkNewsBreaks that summarize corporate news and
information, (3) enhanced press release services, (4) social media
distribution and optimization services, and (5) a full array of
corporate communication solutions. As a multifaceted financial news
and content distribution company with an extensive team of
contributing journalists and writers, NNW is uniquely positioned to
best serve private and public companies that desire to reach a wide
audience of investors, consumers, journalists and the general
public. NNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting
through the overload of information in today’s market, NNW brings
its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW are a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertake no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024
